Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Items 701–800 of 1,001
AGO2 promotes tumor progression in KRAS-driven mouse models of non–small cell lung cancer
Tien, J. C.-Y., Chugh, S., Goodrum, A. E., Cheng, Y., Mannan, R., Zhang, Y., Wang, L., Dommeti, V. L., Wang, X., Xu, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026104118 · Cited by 28
“Intrinsic GTP hydrolysis is compromised in oncogenic RAS variants (3, 4).”
De novo ARF3 variants cause neurodevelopmental disorder with brain abnormality
Sakamoto, M., Sasaki, K., Sugie, A., Nitta, Y., Kimura, T., Gürsoy, S., Çinleti, T., Iai, M., Sengoku, T., Ogata, K., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab224 · Cited by 27
Polyploidy in development and tumor models in Drosophila
Costa, C. A. M., Wang, X., Ellsworth, C. R., & Deng, W. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.011 · Cited by 29
Hu, Q., Masuda, T., Koike, K., Sato, K., Tobo, T., Kuramitsu, S., Kitagawa, A., Fujii, A., Noda, M., Tsuruda, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98485-9 · Cited by 31
Epitranscriptic regulation of HRAS by N 6 -methyladenosine drives tumor progression
Pan, Y., Gu, Y., Liu, T., Zhang, Q., Yang, F., Duan, L., Cheng, S., Zhu, X., Xi, Y., Chang, X., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302291120 · Cited by 32
KRAS and BRAF mutations in Serbian patients with colorectal cancer.
Jakovljevic, K., Malisic, E. J., Cavic, M., Krivokuća, A., Dobričić, J., & Jankovic, R. N. (2012) · PubMed · Cited by 27
Stoppa, G., Rumiato, E., & Saggioro, D. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0676-z · Cited by 25
Yu, C., Merza, M., Luo, L., & Thorlacius, H. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.020 · Cited by 27
Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR
Normanno, N. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1221 · Cited by 28
Lim, C., Kang, X., Mirabella, V. R., Zhang, H., Bu, Q., Araki, Y., Hoang, E. T., Wang, S., Shen, Y., Choi, S., et al. (2017) · Genes & Development · doi:10.1101/gad.294413.116 · Cited by 26
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09344-3 · Cited by 22
Gold(III)–pyrrolidinedithiocarbamato Derivatives as Antineoplastic Agents
Nardon, C., Chiara, F., Brustolin, L., Gambalunga, A., Ciscato, F., Rasola, A., Trevisan, A., & Fregona, D. (2015) · ChemistryOpen · doi:10.1002/open.201402091 · Cited by 28
Giampieri, R., Scartozzi, M., Prete, M. D., Maccaroni, E., Bittoni, A., Faloppi, L., Bianconi, M., Cecchini, L., & Cascinu, S. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.008 · Cited by 25
“[7] Schubbert S, Shannon K, Bollag G.”
BackgroundXia, D., Tian, S., Chen, Z., Qin, W., & Liu, Q. (2018) · Oncology Letters · doi:10.3892/ol.2018.7782 · Cited by 24
Li, L., Fan, Y., Huang, X., Luo, J., Zhong, L., Shu, X., Lu, L., Xiang, T., Chan, A. T. �., Yeo, W., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.007 · Cited by 27
RetractedLi, W., Wang, L., Ji, X.-B., Wang, L., Ge, X. Q., Liu, W., Chen, L., Zheng, Z., Shi, Z., Liu, L.-Z., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01071 · Cited by 25
“Activation of K-RAS could promote the activations of several downstream molecules, such as MAPK and ERK to regulate biological processes (27, 28).”
BackgroundKrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice
Wong, J. C. Y., Pérez-Mancera, P. A., Huang, T. Q., Kim, J., Grego‐Bessa, J., Alzamora, M. D. P., Kogan, S. C., Sharir, A., Keefe, S. H., Morales, C. E., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140495 · Cited by 24
“The discovery of germline mutations in RAS and in genes encoding other proteins involved in Raf/MEK/ERK (Mitogen Activated Protein Kinase; MAPK) signaling delineated dysregulation of this pathway as a unifying mechanism underlying the RASopathy disorders and uncovered a key role of MAPK activation in regulating cell f…”
BackgroundSelf-citationDeterminants of Membrane Orientation Dynamics in Lipid-Modified Small GTPases
Prakash, P., & Gorfe, A. A. (2021) · JACS Au · doi:10.1021/jacsau.1c00426 · Cited by 23
Emerging roles of hnRNP A2B1 in cancer and inflammation
Xu, H., Li, P., Wang, X., Zhuang, H., & Hua, Z. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.104 · Cited by 29
Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?
Ge, M., Zhu, Y., Wei, M., Piao, H., & He, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188996 · Cited by 27
KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice
Fakih, M. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.003 · Cited by 26
Molecular Biology of Lung Cancer—A Review
Pendharkar, D., Bv, A., & Gupta, S. (2013) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-013-0213-3 · Cited by 23
RAB-7 Antagonizes LET-23 EGFR Signaling during Vulva Development in Caenorhabditis elegans
Skorobogata, O., & Rocheleau, C. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036489 · Cited by 27
Li, Y., & Wang, Y. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.449751 · Cited by 27
1H, 13C and 15N resonance assignment for the human K-Ras at physiological pH
Vo, U., Embrey, K. J., Breeze, A. L., & Golovanov, A. P. (2012) · Biomolecular NMR Assignments · doi:10.1007/s12104-012-9413-y · Cited by 25
Phylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa
Pepper, I., Sciver, R. E. V., & Tang, A. (2017) · BMC Evolutionary Biology · doi:10.1186/s12862-017-1024-x · Cited by 25
RAS Regulates the Transition from Naive to Primed Pluripotent Stem Cells
Altshuler, A., Verbuk, M., Bhattacharya, S., Abramovich, I., Haklai, R., Hanna, J. H., Kloog, Y., Gottlieb, E., & Shalom‐Feuerstein, R. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.004 · Cited by 26
Calaf, G. M., Bleak, T. C., & Roy, D. (2021) · Oncology Reports · doi:10.3892/or.2021.7975 · Cited by 28
KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas
Alexander, R. E., López-Beltrán, A., Montironi, R., MacLennan, G. T., Post, K. M., Bilbo, S. A., Jones, T. D., Huang, W., Rao, Q., Sen, J. D., et al. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04309.x · Cited by 30
Gripp, K. W., Bifeld, E., Stabley, D. L., Hopkins, E., Meien, S., Vinette, K. M. B., Sol‐Church, K., & Rosenberger, G. (2012) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35449 · Cited by 26
KATAOKA, M., KITAZAWA, M., NAKAMURA, S., KOYAMA, M., YAMAMOTO, Y., MIYAZAKI, S., HONDO, N., TANAKA, H., & SOEJIMA, Y. (2023) · Anticancer Research · doi:10.21873/anticanres.16629 · Cited by 25
Harlé, A., Filhine-Trésarrieu, P., Husson, M., Boidot, R., Rouyer, M., Dubois, C., Leroux, A., & Merlin, J. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0404-7 · Cited by 25
Brijwani, N., Jain, M., Dhandapani, M., Zahed, F., Mukhopadhyay, P., Biswas, M., Khatri, D., Radhakrishna, V. D., Majumder, B., Radhakrishnan, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01566-x · Cited by 23
Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents
Singh, V. J., Sharma, B., & Chawla, P. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105161 · Cited by 24
Targeting RAS in neuroblastoma: Is it possible?
Lin, L., Miao, L., Lin, H., Cheng, J., Li, M., Zhuo, Z., & He, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108054 · Cited by 24
Lashgari, N., Roudsari, N. M., Zadeh, S. S. T., Momtaz, S., Abbasifard, M., Reiner, Ž., Abdolghaffari, A. H., & Sahebkar, A. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01077-w · Cited by 23
Mechanisms of aneuploidy induction by RAS and RAF oncogenes.
Kamata, T., & Pritchard, C. A. (2011) · Europe PMC (PubMed Central) · Cited by 31
Bruera, G., Cannita, K., Giacomo, D. D., Lamy, A., Troncone, G., Mas, A. D., Coletti, G., Frébourg, T., Sabourin, J. C., Tosi, M., et al. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-135 · Cited by 24
IQGAP1 selectively interacts with K-Ras but not with H-Ras and modulates K-Ras function
Matsunaga, H., Kubota, K., Inoue, T., Isono, F., & Ando, O. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.01.041 · Cited by 23
Dual specificity phosphatases in prostate cancer
Arnoldussen, Y. J., & Saatcioglu, F. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.05.019 · Cited by 24
Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation
Yoshida, R. Y., Ogata, T., Masawa, N., & Nagai, T. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21509 · Cited by 23
Bruera, G., Cannita, K., Giacomo, D. D., Lamy, A., Frébourg, T., Sabourin, J. C., Tosi, M., Alesse, E., Ficorella, C., & Ricevuto, E. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-59 · Cited by 25
The BRAF mutation is associated with the prognosis in colorectal cancer
Ahn, T. S., Jeong, D., Son, M. W., Jung, H., Park, S., Kim, H., Bae, S. B., Kim, H. J., Jeon, Y., Lee, M. S., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1735-y · Cited by 25
“Wildtype KRAS acts as a switch during signal transduction; however, somatic mutations that activate regulators and effectors of Ras proteins are common in tumor development and cancer (Kranenburg 2005; Popescu et al. 1985; Schubbert et al. 2007).”
BackgroundBruera, G., Cannita, K., Tessitore, A., Russo, A. D., Alesse, E., Ficorella, C., & Ricevuto, E. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.10.004 · Cited by 26
Miglietta, G., Gouda, A. S., Cogoi, S., Pedersen, E. B., & Xodo, L. E. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00315 · Cited by 23
Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
Uçar, G., Ergün, Y., Esen, S. A., Açıkgöz, Y., Dirikoç, M., Esen, İ., Bal, Ö., & Uncu, D. (2020) · Medicine · doi:10.1097/md.0000000000022407 · Cited by 25
“Activating RAS mutations cause the deterioration of RAS protein activity; in this way GTPase activity is decreased, the protein becomes resistant to GTP hydrolysis by GTPase, resulting in a structurally active GTP-bound protein and a continuous growth stimulus.([7,8]) Therefore, oncogenic activity occurs.”
BackgroundYu, S.-H., Wang, T., & Au, L. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.027 · Cited by 24
Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto, S., Fukami, T., Yagi, H., Kuroki, M., & Yotsumoto, F. (2009) · PubMed · Cited by 27
Park, H., Lee, S. H., Sung, K. W., Koo, H. H., Jung, N. G., Cho, B., Kim, H. K., Park, I.-A., Lee, K.-O., Ki, C., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1326-9 · Cited by 23
Beloueche‐Babari, M., Jamin, Y., Arunan, V., Walker‐Samuel, S., Revill, M., Smith, P. D., Halliday, J. L., Waterton, J. C., Barjat, H., Workman, P., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.456 · Cited by 22
Halder, A. K., Giri, A. K., & Cordeiro, M. N. D. S. (2019) · Molecules · doi:10.3390/molecules24213909 · Cited by 24
“Aberration of the extracellular regulated kinase (ERK) pathway is associated with the prognosis of numerous human cancers including lung, kidney, ovary, colon and pancreas [3].”
BackgroundLim, C., Xu, J.-C., Chen, T., Xu, J., Chen, W., Hu, J., Li, Q., & Zhang, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1137-y · Cited by 23
Scheiter, A., Evert, K., Reibenspies, L. E., Cigliano, A., Annweiler, K., Müller, K., Pöhmerer, L., Xu, H., Cui, G., Itzel, T., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13135 · Cited by 25
CRISPR and KRAS: a match yet to be made
Bender, G., Yamaci, R. F., & Taneri, B. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00772-0 · Cited by 30
SYT8 promotes pancreatic cancer progression via the TNNI2/ERRα/SIRT1 signaling pathway
Fu, Z., Liang, X., Shi, L., Tang, L., Chen, D., Liu, A., & Shao, C. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00779-4 · Cited by 22
“Activated Ras further triggers the RAF/mitogen-activated protein and phosphoinositide-3-kinase/AKT signaling pathways that activate key downstream transcription factors to promote cell proliferation [5].”
BackgroundMolecular characterization of head and neck cancer: how close to personalized targeted therapy?
Worsham, M. J., Ali, H. Y., Dragovic, J., & Schweitzer, V. P. (2012) · PubMed · doi:10.2165/11635330-000000000-00000 · Cited by 22
Dementiev, A. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.04.021 · Cited by 22
Sacco, E., Metalli, D., Spinelli, M., Manzoni, R., Šamalíková, M., Grandori, R., Morrione, A., Traversa, S., Alberghina, L., & Vanoni, M. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.05.011 · Cited by 25
Coyle, S. M., & Lim, W. A. (2016) · eLife · doi:10.7554/elife.12435 · Cited by 23
“Mutations in these important molecules are often associated with cancer or other diseases (Bos, 1989; Schubbert et al., 2007).”
BackgroundZhao, Y., Pang, D., Wang, C., Zhong, S., & Wang, S. (2016) · Tumor Biology · doi:10.1007/s13277-016-5027-9 · Cited by 24
Structural characterization of 14-3-3ζ in complex with the human Son of sevenless homolog 1 (SOS1)
Ballone, A., Centorrino, F., Wolter, M., & Ottmann, C. (2018) · Journal of Structural Biology · doi:10.1016/j.jsb.2018.01.011 · Cited by 20
Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients
Hamzehzadeh, L., Khadangi, F., Karimiani, E. G., Pasdar, A., & Kerachian, M. A. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.05.001 · Cited by 24
Never Say Die: Survival Signaling in Large Granular Lymphocyte Leukemia
Shah, M. V., Zhang, R., & Loughran, T. P. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.019 · Cited by 24
Dahse, R., Driemel, O., Schwarz, S., Kromeyer-Hauschild, K., Berndt, A., & Kosmehl, H. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.01.013 · Cited by 24
Smith, M. L., & McKerrell, T. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch3 · Cited by 22
Personalized treatment for advanced colorectal cancer: KRAS and beyond
Karapetis, C. S., & Patel, G. S. (2013) · Cancer Management and Research · doi:10.2147/cmar.s35025 · Cited by 23
Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
Kline, C., & El‐Deiry, W. S. (2013) · Pharmaceuticals · doi:10.3390/ph6080988 · Cited by 25
Recent discoveries in the genetics of melanoma and their therapeutic implications
Marquette, A., Bagot, M., Bensussan, A., & Dumaz, N. (2007) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-007-0043-5 · Cited by 24
Park, J., Jeong, W.-J., Kim, M., Min, D., & Choi, K. (2016) · Journal of Cell Science · doi:10.1242/jcs.184366 · Cited by 24
Halakou, F., Sen-Kilic, E., Cukuroglu, E., Keskin, Ö., & Gürsoy, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-07351-0 · Cited by 22
Sciver, R. E. V., Lee, M., Lee, C., Lafever, A., Svyatova, E. A., Kanda, K., Collier, A. L., van Reesema, L. L. S., Tang-Tan, A. M., Zheleva, V. P., et al. (2018) · Cancers · doi:10.3390/cancers10050142 · Cited by 21
Protective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach
Advani, D., Gupta, R. V., Tripathi, R. S., Sharma, S., Ambasta, R. K., & Kumar, P. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104841 · Cited by 25
Chen, Q., Lin, W., Zhou, X.-X., Cao, Z., Feng, X., Gao, Y., & He, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107060 · Cited by 26
H-Ras regulation of TRAIL death receptor mediated apoptosis
Chen, J., Bozza, W. P., Di, X. M., Zhang, Y., Hallett, W. H. D., & Zhang, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2091 · Cited by 21
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women
Phipps, A. I., Makar, K. W., & Newcomb, P. A. (2013) · International Journal of Colorectal Disease · doi:10.1007/s00384-013-1715-8 · Cited by 22
RAS, BRAF, and TP53 Gene Mutations in Taiwanese Colorectal Cancer Patients
Chang, Y., Chang, S., Yeh, K., Lin, T.-H., & Chang, J. (2013) · Onkologie · doi:10.1159/000356814 · Cited by 22
RAS and Hedgehog - partners in crime
Lauth, M. (2011) · Frontiers in bioscience · doi:10.2741/3852 · Cited by 24
Caiola, E., Brunelli, L., Marabese, M., Broggini, M., Lupi, M., & Pastorelli, R. (2016) · Oncotarget · doi:10.18632/oncotarget.9849 · Cited by 22
Modeling RASopathies with Genetically Modified Mouse Models
Hernández-Porras, I., & Guerra, C. E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6424-6_28 · Cited by 24
Ketzer, S., Schimmel, K. J. M., Koopman, M., & Guchelaar, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0590-9 · Cited by 25
Jin, X., Qin, T., Zhao, M., Bailey, N. G., Liu, L., Yang, K. B., Ng, V., Higashimoto, T., Coolon, R., Ney, G. M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017400 · Cited by 23
“Activating RAS mutations are prevalent in human cancers, including hematologic malignancies.(23,24) In CMML, oncogenic NRAS and KRAS mutations are found in ;15% to 40% of patients(4,25,26) and are associated with a more proliferative phenotype.”
BackgroundProtein phase separation: A novel therapy for cancer?
Wang, W., Chen, Y., Xu, A., Cai, M., Cao, J., Zhu, H., Yang, B., Shao, X., Ying, M., & He, Q. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15242 · Cited by 21
“Moreover, hyperactive Ras transduction is found in various cancers, conferring the aberrant functional properties of malignant cells, dysregulated cell growth, differentiation and survival (Schubbert et al., 2007).”
BackgroundMultiple versus solitary giant cell lesions of the jaw: Similar or distinct entities?
Schreuder, W. H., van der Wal, J. E., de Lange, J., & van den Berg, H. (2021) · Bone · doi:10.1016/j.bone.2021.115935 · Cited by 23
Dekker, F. J., & Hedberg, C. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.11.025 · Cited by 21
Yamasaki, M., Iwase, M., Kawano, K., Sakakibara, Y., Suiko, M., Ikeda, M., & Nishiyama, K. (2013) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.13-57 · Cited by 20
Gondal, M. N., & Chaudhary, S. U. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.712505 · Cited by 34
“(62) employed COSMIC’s mutation data to investigate Ras activity in cancers as well as developmental disorders.”
MethodEmerging Role of Autophagy in the Development and Progression of Oral Squamous Cell Carcinoma
El-Aziz, Y. S. A., Leck, L. Y. W., Jansson, P. J., & Sahni, S. (2021) · Cancers · doi:10.3390/cancers13246152 · Cited by 24
Zebrafish Congenital Heart Disease Models: Opportunities and Challenges
Yang, D., Jian, Z., Tang, C., Chen, Z., Zhou, Z., Zheng, L., & Peng, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115943 · Cited by 23
“The aberrant activation of the Mapk signaling pathway reportedly impairs ciliary function [176], particularly in NS, where pathogenic mutations in NS-related genes enhance this signaling cascade [177,178].”
BackgroundMolecular Characterization of Head and Neck Cancer: How Close to Personalized Targeted Therapy?
Worsham, M. J., Ali, H. Y., Dragovic, J., & Schweitzer, V. P. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/bf03262210 · Cited by 32
Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors
Buchstaller, H., Burgdorf, L. T., Finsinger, D., Stieber, F., Sirrenberg, C., Amendt, C., Grell, M., Zenke, F. T., & Krier, M. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.108 · Cited by 20
Comparison of K-ras mutations in lung, colorectal and gastric cancer
Peng, N., & Zhao, X.-T. (2014) · Oncology Letters · doi:10.3892/ol.2014.2205 · Cited by 18
Long Noncoding RNA MIR4697HG Promotes Cell Growth and Metastasis in Human Ovarian Cancer
Zhang, L.-Q., Yang, S., Wang, Y., Fang, Q., Chen, X.-J., Lu, H., & Zhao, L.-P. (2017) · Analytical Cellular Pathology · doi:10.1155/2017/8267863 · Cited by 20
Molecular Recognition of Colon Cancer Biomarkers: P53, KRAS and CEA in Whole Blood Samples
Gugoaşă, L. A., Staden, R. S., Al-Ogaidi, A. J. M., Stanciu‐Găvan, C., van Staden, J. F., Roşu, M., & Pruneanu, S. M. (2017) · Journal of The Electrochemical Society · doi:10.1149/2.1191709jes · Cited by 20
Scaffold-based design of kinase inhibitors for cancer therapy
Zhang, C., & Bollag, G. E. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.10.010 · Cited by 22
Self-citationLow Incidence of Oncogenic EGFR, HRAS, and KRAS Mutations in Seborrheic Keratosis
Georgieva, I. A., Mauerer, A., Groesser, L., Herschberger, E., Aslanidis, C., Dietmaier, W., Landthaler, M., & Hafner, C. M. (2013) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e31828c0542 · Cited by 21
Sakai, E., Fukuyo, M., Matsusaka, K., Ohata, K., Doi, N., Takane, K., Matsuhashi, N., Fukushima, J., Nakajima, A., & Kaneda, A. (2016) · Cancer Science · doi:10.1111/cas.12930 · Cited by 20
Biomarker-driven and molecular targeted therapies for colorectal cancers
Schirripa, M., Cohen, S. A., Battaglin, F., & Lenz, H. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.003 · Cited by 27
“KRAS is a small GTPase protein member of the RAS family [9,10], and its constitutive activation, gained through somatic gene mutations, results in cell proliferation and survival independent of external cellular signals [11].”
BackgroundHu, Y., Tao, S.-Y., Deng, J.-M., Hou, Z., Liang, J., Huang, Q.-G., Li, L.-H., Li, H., Chen, Y., Hua, Y., et al. (2018) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2018.19.11.3001 · Cited by 21
Awada, A. H., Vandone, A. M., & Aftimos, P. G. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283521349 · Cited by 23
RAS pathway: The new frontier of brain mosaicism in epilepsy
Sran, S., & Bedrosian, T. A. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106074 · Cited by 23
“long been associated with CNS tumors and cause approximately 30% of all cancers (Prior et al., 2012; Schubbert et al., 2007); however, only recently have these genes been directly implicated in focal epilepsy.”
Background
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.